Shinya Rai
A5004550999- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- CNS Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Chronic Myeloid Leukemia Treatments
- Cancer-related gene regulation
- Cancer Genomics and Diagnostics
- Cellular transport and secretion
- Gastrointestinal Tumor Research and Treatment
- Histone Deacetylase Inhibitors Research
- Immunotherapy and Immune Responses
- Vector-Borne Animal Diseases
- Retinoids in leukemia and cellular processes
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Erythrocyte Function and Pathophysiology
- Cell Adhesion Molecules Research
- Galectins and Cancer Biology
Kindai University
2014-2024
Kindai University Hospital
2018-2024
Spinal Cord Injury BC
2022-2024
Osaka University Hospital
2023
Soai University
2021
Chinese General Hospital College of Nursing and Liberal Arts
2010
Long Island Jewish Medical Center
2004
North Shore University Hospital
2004
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) untreated DLBCL. PATIENTS AND METHODS Patients were randomly assigned at a one-to-one ratio to (560 mg per day orally) R-CHOP or placebo R-CHOP. The primary end point was event-free survival (EFS) the intent-to-treat (ITT) population activated (ABC) DLBCL...
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients relapsed, recurrent, or refractory disease. We evaluated the efficacy safety of valemetostat, a potent enhancer zeste homolog 2 (EZH2) EZH1 inhibitor, in treating relapsed (R/R) ATL. This multicenter phase trial enrolled R/R ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease unacceptable...
Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted multicenter, phase II study of tirabrutinib in patients treatment-naïve (Cohort A) or relapsed/refractory B) Waldenström's macroglobulinemia (WM). Patients were treated 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall (ORR; minor response), time to (TTMR), progression-free survival...
Tazemetostat is a selective, reversible, small-molecule inhibitor of the histone methyltransferase enzyme, enhancer zest homolog 2 (EZH2). In this multicenter, open-label, phase II study, we assessed efficacy and safety tazemetostat in Japanese patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma harboring EZH2 mutation. (800 mg twice daily) was given orally (28-day cycle) until disease progression unacceptable toxicity. Among 20 eligible patients, 17 were enrolled cohort 1...
Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks I and IIb HDAC. This multicenter phase study aimed to investigate the efficacy safety tucidinostat, 40 mg twice per week (BIW), in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). The primary endpoint was overall response rate (ORR) assessed by independent review committee. Between March 2017 2019, 55 were treated,...
In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared vincristine, (R-CHOP) similar safety. Patients were randomized 1:1 to 6 cycles of Pola-R-CHP or R-CHOP 2 alone. For registration China, consistency PFS an Asia subpopulation (defined as ≥50% risk reduction expected global population) was...
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2 , rituximab 375 (pola + BR) Q3W for up six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line therapy and were ineligible autologous stem cell transplantation (ASCT) or experienced treatment failure ASCT....
The phase II study of tirabrutinib monotherapy at a daily dose 480 mg under fasting conditions for treatment-naïve and relapsed/refractory Waldenström's macroglobulinemia (ONO-4059-05 study) demonstrated promising efficacy tolerable safety profile. We conducted an unplanned analysis with median follow-up 24.8 months to update the results report patient-reported quality life. Of 27 enrolled patients, 22 patients continued receiving drug. major response assessed by independent review committee...
About a third of patients with relapsed or refractory classic Hodgkin lymphoma (r/r CHL) succumb to their disease after high-dose chemotherapy followed by autologous stem-cell transplantation (HDC/ASCT). Here, we aimed describe spatially resolved tumor microenvironment (TME) ecosystems establish novel biomarkers associated treatment failure in r/r CHL.
Phosphatidylinositol binding clathrin assembly protein (PICALM), also known as lymphoid myeloid leukemia (CALM), was originally isolated part of the fusion gene CALM/AF10, which results from chromosomal translocation t(10;11)(p13;q14). CALM is sufficient to drive in vitro on lipid monolayers and regulates clathrin-coated budding size shape vesicles at plasma membrane. However, physiological role has yet be elucidated. Here, vivo investigated using CALM-deficient mice. mice exhibited retarded...
PRAME is a prominent member of the cancer testis antigen family proteins, which triggers autologous T cell-mediated immune responses. Integrative genomic analysis in diffuse large B cell lymphoma (DLBCL) uncovered recurrent and highly focal deletions 22q11.22, including gene, were associated with poor outcome. PRAME-deleted tumors showed cytotoxic escape cold tumor microenvironments. In addition, downmodulation was strongly somatic EZH2 Y641 mutations DLBCL. turn, PRC2-regulated genes...
The tissue architecture of classic Hodgkin Lymphoma (CHL) is ｕｎｉｑｕｅ among cancers and characterized by rare malignant Reed-Sternberg cells that co-evolve with a complex ecosystem immune in the tumor microenvironment (TME). lack comprehensive systems-level interrogation has hindered description disease heterogeneity clinically relevant molecular subtypes. Here, we employed an integrative, multimodal approach to characterize CHL tumors using cell sequencing, spatial transcriptomics imaging...
Iron overload is the accumulation of excess iron in body that may occur as a result various genetic disorders or consequence repeated blood transfusions. The surplus then stored liver, pancreas, heart and other organs, which lead to chronic liver disease cirrhosis, diabetes disease, respectively. In addition, excessive impair hematopoiesis, although mechanisms this deleterious effect not entirely known. study, we found ferrous ammonium sulfate (FeAS), induced growth arrest apoptosis immature...
Abstract Previously, we reported the efficacy and safety of tazemetostat in Japanese patients with relapsed/refractory follicular lymphoma (FL) diffuse large B-cell (DLBCL) harboring EZH2 mutation a multicenter, open-label, phase II study. Here, present follow-up analysis at long-term median 35.0 months. Twenty were enrolled: 17 FL cohort three DLBCL cohort. In cohort, objective response rate was 70.6%, consistent primary analysis, progression-free survival (PFS) not reached. The 24-month...
Abstract Mutated receptor tyrosine kinases (MT-RTKs) such as internal tandem duplication of FMS-like kinase 3 (FLT3 ITD) and a point mutation KIT D816V are driver mutations for acute myeloid leukemia (AML). Clathrin assembly lymphoid protein (CALM) regulates intracellular transport RTKs, however, the precise role MT-RTKs remains elusive. We here show that CALM knock down leads to severely impaired FLT3 ITD- or D814V-dependent cell growth compared marginal influence on wild-type FLT3-...
We previously examined the utility of rituximab-bendamustine (RB) in patients with follicular lymphoma (FL) exhibiting less than optimal responses to 2 cycles R-CHOP chemotherapy regimen. The aim this study was identify molecular biomarkers that can predict prognosis RB-treated context prospective cohort. first analyzed mutational status 410 genes diagnostic tumor specimens by target capture and Sanger sequencing. CREBBP, KMT2D, MEF2B, BCL2, EZH2, CARD11 were recurrently mutated as reported...
Abstract This single‐arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)‐guided therapy for newly diagnosed advanced‐stage classic Hodgkin lymphoma (cHL). Patients aged 16–60 years with cHL received two cycles doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) then underwent an iPET scan (PET2), which was centrally reviewed using a five‐point Deauville scale. PET2‐negative patients continued additional four ABVD, whereas...
We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL received HDC/ASCT our institution, including 12 (26.1%), who as an upfront setting (UFS). At a median follow-up time 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) UFS, 57.8% 38.1-73.2%) relapsed or refractory...